Programme Category
Programme Name
Programme Description
The Programme aims to improve and promote health in the Union to reduce the burden of communicable and non-communicable diseases by:
- protecting people from serious cross-border health threats
- improving the availability, accessibility and affordability of medicines, medical devices and other crisis-related products in the EU
- strengthening national health systems
Identifier Code
Call
Summary
The aim of the action is to identify potential viable effective anti-cancer drugs by making use and piloting ‘in-silico drug repurposing’ including by upscaling available innovation using advanced computing and the new big-data technologies and high-performance computing while reducing timeframes and development costs.
Detailed Call Description
The action will launch an EU platform based on ‘computational drug networks’ to predict, in-silico, the efficacy of approved drugs against relevant cancer targets, as well as to select better responder patients or disease biomarkers. This will be implemented following a time and cost-effective approach, also building on experiences with repurposing of medicines to treat COVID-19, where high-performance computing will be used to rapidly test existing molecules and new drug combinations.
The action will also devise and test models for closer collaboration among stakeholders.
EXPECTED RESULTS AND IMPACT
The launch of an EU platform based on improved ‘computational drug networks’ is expected to result in a better prediction of the efficacy of approved drugs against relevant cancer targets, as well as to select better responder patients or disease biomarkers, and to link Member States’ structures responsible for cancer treatment and care.
This work will help to improve the arsenal of anticancer drugs and overcome certain limitations of modern cancer therapies against old and new therapeutic targets in oncology.
The action is likely to increase available anticancer drugs and overcome limitations of current cancer therapies against old and new therapeutic targets in oncology, to the final benefit of patients with poor prognosis and rare cancers.
Call Total Budget
Financing percentage by EU or other bodies / Level of Subsidy or Loan
60%
Applicants can apply for a higher project funding rate (maximum 80%) if your project is of ‘exceptional utility’.
Thematic Categories
- Health
- Information Technology
Eligibility for Participation
- Central Government
- International Organisations
- NGOs
- Non Profit Organisations
- Private Bodies
- State-owned Enterprises
Eligibility For Participation Notes
In order to be eligible for funding, the applicants (beneficiaries and affiliated entities) must:
- be legal entities (public or private bodies) created under Union law or an international organisation, or
- be established in one of the eligible countries, i.e.:
- EU Member States (including overseas countries and territories linked to it (OCTs)
- eligible non-EU countries: EEA countries and countries associated to the EU4Health Programme (third countries, candidate countries and potential candidate countries, neighbourhood countries) or countries which are in ongoing negotiations for an association agreement and where the agreement enters into force before grant signature.
Call Opening Date
Call Closing Date
National Contact Point(s)
Ministry of Health, Department of European Affairs
Ms MAKRIGIORGI Elena
emakrigiorgi@moh.gov.cy
(Publish Date: 29/10/2021-for internal use only)
EU Contact Point
Stefan DE KEERSMAECKER
Telephone: +32 2 298 46 80
Email: stefan.de-keersmaecker@ec.europa.eu
Darragh CASSIDY
Telephone: +32 2 298 39 78
Email: darragh.cassidy@ec.europa.eu